Directed Share Issue
Oncopeptides is a clinical development pharmaceutical company focused on conducting anti-cancer research to develop treatments for the benefit of patients. Oncopeptides’ lead product candidate is Ygalo (melflufen), the first peptidase potentiated cytotoxic therapy intended for use in the treatment of multiple myeloma.